462
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial

, , , &
Pages 1199-1205 | Received 04 Nov 2019, Accepted 03 Feb 2020, Published online: 01 Mar 2020

References

  • Bensmail D, Vermersch P. Epidemiology and clinical assessment of spasticity in multiple sclerosis. Rev Neurol (Paris) 2012;168(Suppl 3):S45–S50.
  • Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15(3):146–158.
  • Bethoux F, Marrie RA. A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis. Patient 2016;9(6):537–546.
  • Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis - Clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154–162.
  • Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: The CANDLE study. Int J Neurosci. 2013;123(12):850–858.
  • Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386–1396.
  • Henze T, Feneberg W, Flachenecker P, et al. What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 2017;88(12):1428–1434.
  • eMC Sativex Oromucosal Spray SPC. 2018. [cited 2019 September 5]. Available from: https://www.medicines.org.uk/emc/history/23262.
  • Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo- controlled study on 160 patients. Mult Scler. 2004;10(4):434–441.
  • Collin C, Davies P, Mutiboko IK, et al.; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296.
  • Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459.
  • Novotna A, Mares J, Ratcliffe S, et al.; The Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel- group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
  • Markovà J, Essner U, Akmaz B, et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129(2):119–128.
  • Lucchinetti C, Brack W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.